News

For a total overview over all Hexvix and Photocure news, please visit www.photocure.com

Here are the latest news from Hexvix:

NEW DATA PRESENTED ON BLUE LIGHT CYSTOSCOPY WITH CYSVIEW®/HEXVIX® AT THE SOCIÉTÉ INTERNATIONALE D’UROLOGIE (SIU) 2016 ANNUAL MEETING

Oslo, Norway, October 25, 2016 Photocure ASA announced that new data on Blue Light Cystoscopy with Cysview®/Hexvix® were presented at the Société Internationale d’Urologie (SIU) Annual meeting, October 20th to 23rd, Buenos Aires, Argentina: an ePoster from a US registry study and an ePoster video on Blue Light Flexible Cystoscopy.


Positive clinical data on blue light cystoscopy with Cysview®/Hexvix® presented at AUA

Oslo, Norway, May 9, 2016 — Photocure ASA announced today new data from a prospective multicenter ongoing registry study that shows Blue Light Cystoscopy (BLC) with Cysview® increases detection rates of flat, more aggressive non-muscle invasive bladder cancer lesions (carcinoma in situ (CIS)) as well papillary lesions over white light cystoscopy (WLC) alone. The data from the prospective registry, real life, study including 175 patients, was presented at the American Urological Association (AUA) annual meeting in San Diego, CA, May 6-10, 2016.


Enhanced cystoscopy including blue light cystoscopy with Cysview®/Hexvix® is recommended in the new AUA/SUO bladder cancer guideline

Oslo, Norway, May 2, 2016: Photocure ASA announced today the American Urological Association (AUA) and the Society of Urological Oncology (SUO) have included enhanced cystoscopy in the 2016 Guidelines for the management of non-muscle invasive bladder cancer (NMIBC). Enhanced cystoscopy including Blue Light Cystoscopy (BLC) with Cysview®/Hexvix® is recommended for increasing the detection and reducing recurrence of NMIBC.